Status:

TERMINATED

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

Lead Sponsor:

Abbott Diabetes Care

Conditions:

Diabetes Mellitus

Eligibility:

All Genders

4-17 years

Brief Summary

This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Gluco...

Detailed Description

Up to 400 pediatric subjects aged 4-17 years with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes, will be enrolled to obtain at least 314 subjects who c...

Eligibility Criteria

Inclusion

  • Subject must be 4 - 17 years of age.
  • Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment.
  • Subject is currently using SMBG for managing their diabetes.
  • Subject and/or caregiver must be able to read and understand English .
  • In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
  • Subject and/or caregiver must have access to an internet connected computer for uploading data from the blood glucose meter and FreeStyle Libre system.
  • Subject must have an overnight companion (caregiver 18 years or older) present in the same home during participation of the study.
  • Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.

Exclusion

  • Subject and/or caregiver is a member of the Site Staff.
  • Subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes
  • Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
  • Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment.
  • Subject is on dialysis at the time of enrollment.
  • Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.
  • Subject currently is participating in another clinical trial.
  • Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Key Trial Info

Start Date :

February 27 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 13 2020

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT03448367

Start Date

February 27 2018

End Date

October 13 2020

Last Update

February 5 2021

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Sansum Diabetes Research Institute

Santa Barbara, California, United States, 93105

2

Barbara Davis Center for Diabetes

Aurora, Colorado, United States, 80045

3

Rocky Mountain Diabetes & Osteoporosis Center

Idaho Falls, Idaho, United States, 83404

4

Albuquerque Neuroscience Inc.

Albuquerque, New Mexico, United States, 87109